GBM

This early-phase study tests whether adding the experimental drug S-Gboxin to standard radiation and chemotherapy can help people with glioblastoma or diffuse midline glioma, two aggressive brain cancers. About 10 participants whose tumors have returned or worsened will receive t…

This study tests a combination of a drug called niraparib and a device that delivers low-intensity electric fields (Tumor-Treating Fields) in 30 adults whose glioblastoma brain tumor has come back after radiation. The goal is to see if this treatment can shrink or stabilize the t…

This study tests a drug called niraparib in people with two types of brain tumors: newly diagnosed glioblastoma and recurrent IDH-mutant glioma with ATRX loss. The goal is to see if the drug reaches the tumor and slows its growth. Up to 42 participants will receive niraparib befo…

This early-phase trial tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can boost the immune system's attack on glioblastoma, an aggressive brain cancer. About 63 patients with recurrent glioblastoma will receive the drugs or a placebo before…

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This study tests a new drug called LP-184 in people with advanced solid tumors (like certain breast, lung, or pancreatic cancers) that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 64 participan…

This trial tests a device implanted in the skull that uses ultrasound to temporarily open the blood-brain barrier, allowing chemotherapy drugs to reach brain tumors more effectively. About 57 adults with recurrent glioblastoma will receive this treatment after surgery to remove t…

This study tests whether a new type of imaging scan can predict how well glioblastoma patients respond to treatment. Ten participants will receive standard care plus an experimental drug called BPM31510. The goal is to see if the scan can forecast survival and tumor progression.